Promotion of physical health in persons with schizophrenia: can we prevent cardiometabolic problems before they begin?

Acta Psychiatrica Scandinavica

Volumn 132, Issue 2, 2015, Pages 83-85

  Mitchell, A J ^a   De Hert, M ^b,c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

FITNESS; HEALTH PROMOTION; HEART DISEASES; HUMAN; LIFESTYLE; METABOLIC DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HEALTH PROMOTION; HEART DISEASES; HUMANS; LIFE STYLE; METABOLIC DISEASES; PHYSICAL FITNESS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84953844176     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12466     Document Type: Editorial

References (21)

1. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull 2013;39:306–318.
2. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? – a comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 2013;39:295–305.
3. Soundy A, Wampers M, Probst M et al. Physical activity and sedentary behaviour in outpatients with schizophrenia: a systematic review and meta-analysis. IJTR 2013;20:588–595.
4. Janney CA, Ganguli R, Richardson CR et al. Sedent-ary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffec-tive disorders (WAIST Study). Schizophr Res 2013;145:63–68.
5. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125–147.
6. Mitchell AJ, Vancampfort D, De Hert M, Stubbs B. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. Gen Hosp Psychiatry 2015;37:14–23.
7. Barber JA, Palmese L, Reutenauer EL, Grilo CM, Tek C. Implications of weight-based stigma and self-bias on quality of life among individuals with schizophrenia. J Nerv Ment Dis 2011;199:431–435.
8. Correll CU, Detraux J, de Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119–136.
9. Rosenbaum S, Tiedemann A, Sherrington C, Curtis J, Ward PB. Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry 2014;75:964–974.
10. Fernández-San-martín MI, Martín-López LM, Masa-Font R et al. The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: meta-analysis of intervention studies. Community Ment Health J 2014;50:81–95.
11. Gierisch JM, Nieuwsma JA, Bradford DW et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 2014;75:e424–e440.
12. Attux C, Martini LC, Araújo CM, Roma AM, Reis AF, Bressan RA. The effectiveness of a non-pharmacological intervention for weight gain management in severe mental disorders: results from a national multicentric study. Rev Bras Psiquiatr 2011;33:117–121.
13. Bernardo M, Cañas F, Banegas JR et al. Prevalance and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009;24:431–441.
14. Ward M, Benjamin Druss B. The epidemiology of diabe-tes in psychotic disorders. Lancet Psychiatry 2015;2:431–451.
15. Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 2015;11:79–89.
16. Holt RIG. The prevention of diabetes and cardiovascular disease in people with schizophrenia. Acta Psychiatr Scand 2015;132:86–96.
17. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015;132:144–157.
18. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 2015;132:97–108.
19. Moore S, Shiers D, Daly B, Mitchell AJ, Gaughran F. Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Acta Psychiatr Scand 2015;132:109–121.
20. Stubbs B, Vancampfort D, Bobes J, De Hert M, Mitchell AJ. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatr Scand 2015;132:122–130.
21. Vancampfort D, Rosenbaum S, Probst M et al. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis. Acta Psychiatr Scand 2015;132:131–143.